Morphocell Technologies has expanded its Series A funding to $50 million with a new $10 million investment led by Investissement Québec and CDP Venture Capital to advance its tissue-engineered therapeutics for regenerative medicine.
Announced Monday, the additional funding builds on the initial $40 million Series A round led by Genson Capital in February 2024. According to the company, the combined investment extends its operational runway to more than three years and positions Morphocell among Canada’s best-funded private companies in the regenerative medicine sector.
“Since our initial Series A close, Morphocell has delivered remarkable progress across development, manufacturing and team expansion. The decision by Investissement Québec to deepen its commitment and by CDP Venture Capital to join our syndicate represents a powerful vote of confidence in our vision and execution. Their support further validates the global impact potential of our tissue-engineered therapies and strengthens our capacity to create transformative solutions to patients living with liver disease,” CEO Massimiliano Paganelli said in a statement.
Alongside the announcement, Morphocell announced the creation of a new subsidiary in Italy, which will serve as the company’s entry point into the European market.
